Related Experiment Video

Updated: Jun 22, 2026

Rapid Point-of-Care Assay of Enoxaparin Anticoagulant Efficacy in Whole Blood
11:17

Rapid Point-of-Care Assay of Enoxaparin Anticoagulant Efficacy in Whole Blood

Published on: October 12, 2012

The need for new oral anticoagulants in clinical practice

Elaine M Hylek1

  • 1Department of Medicine, Boston University School of Medicine, Boston, Massachusetts 02118, USA. ehylek@bu.edu

Journal of Cardiovascular Medicine (Hagerstown, Md.)
|July 3, 2009
PubMed

Insights

Atrial fibrillation increases stroke risk, and current treatments like warfarin have practical limitations. New oral anticoagulants are needed for effective stroke prevention in atrial fibrillation patients.

Area of Science:

  • Cardiology
  • Pharmacology

Background:

  • Atrial fibrillation is a major risk factor for stroke.
  • Vitamin K antagonists, such as warfarin, are standard oral anticoagulants for stroke prevention in atrial fibrillation.
  • Warfarin use is limited by challenges in routine clinical practice, including underuse, especially in elderly patients.

Purpose of the Study:

  • To highlight the challenges associated with warfarin therapy in atrial fibrillation patients.
  • To emphasize the need for novel oral anticoagulants with improved convenience and tolerability.

Main Methods:

  • Literature review on atrial fibrillation, stroke risk, and oral anticoagulants.
  • Analysis of clinical practice challenges with warfarin.
  • Identification of requirements for new anticoagulant therapies.

Main Results:

  • Warfarin is underutilized despite proven efficacy in reducing stroke risk.
  • Physician hesitancy and patient-specific factors contribute to suboptimal warfarin use.
  • Existing anticoagulants require frequent monitoring and dose adjustments.

Conclusions:

  • There is a significant unmet need for new oral anticoagulants in atrial fibrillation management.
  • Novel anticoagulants should offer convenience, better tolerability, and reduced monitoring requirements.
  • Improved stroke prevention strategies are crucial for patients with atrial fibrillation.

Related Concept Videos

Anticoagulant Drugs: Vitamin K Antagonists and Direct Oral Anticoagulants01:18

Anticoagulant Drugs: Vitamin K Antagonists and Direct Oral Anticoagulants

Oral anticoagulants are vital tools in preventing and treating blood clotting disorders. This diverse class of medications can be categorized as vitamin K antagonists, exemplified by warfarin, and direct thrombin inhibitors (DTIs), such as dabigatran, as well as factor Xa inhibitors, including rivaroxaban.
Warfarin, a prominent vitamin K antagonist family member, exerts its effect by inhibiting the enzyme VKORC1 (vitamin K epoxide reductase complex 1). By hindering this enzyme, warfarin...
Anticoagulant Drugs: Low-Molecular-Weight Heparins01:30

Anticoagulant Drugs: Low-Molecular-Weight Heparins

Hemostasis is a crucial process that prevents excessive blood loss from damaged blood vessels. It involves various mechanisms such as vasoconstriction, platelet adhesion and activation, and fibrin formation. The importance of each mechanism depends on the type of vessel injury. In contrast, thrombosis is the abnormal formation of a blood clot within the blood vessels, leading to potential complications if the clot obstructs blood flow. Thrombosis can be caused by increased coagulability of the...
Venous Thrombosis III: Interprofessional Care01:29

Venous Thrombosis III: Interprofessional Care

Venous thrombosis requires effective prevention and treatment strategies to improve patient outcomes and reduce potential complications.Prevention StrategiesHealthcare providers must prioritize preventing venous thromboembolism (VTE) for all adult patients upon admission. Interventions depend on bleeding and thrombosis risk, medical history, current medications, diagnoses, planned procedures, and patient preferences. Patients on bed rest should change positions every two hours and, if not...
Antiplatelet Drugs: Prostaglandin Synthesis, P2Y12 and Glycoprotein IIb/IIIa Inhibitors01:20

Antiplatelet Drugs: Prostaglandin Synthesis, P2Y12 and Glycoprotein IIb/IIIa Inhibitors

Antiplatelet drugs emerge as frontline defenders against the insidious threat of thromboembolic diseases, where abnormal clots obstruct vital blood vessels. These drugs stand as bulwarks, inhibiting platelet aggregation and clot formation, thereby mitigating the risk of life-threatening conditions like myocardial infarction, coronary artery disease, and thrombotic strokes.
Prostaglandin synthesis inhibitors, exemplified by the widely known aspirin, wield their power by irreversibly acetylating...
Oral Drug Delivery Systems: Introduction01:23

Oral Drug Delivery Systems: Introduction

Oral drug delivery is the most common route of administration due to its convenience, cost-effectiveness, and high patient compliance. It enables precise formulation to ensure proper drug dosage and bioavailability. The development of oral dosage forms considers drug properties such as solubility, stability, and absorption to optimize therapeutic efficacy.Tablets, capsules, liquids, and chewable formulations enhance drug stability, mask undesirable tastes, and improve patient experience.
Pulmonary Embolism II: Diagnostic Studies and Interprofessional Care01:29

Pulmonary Embolism II: Diagnostic Studies and Interprofessional Care

Diagnosing Pulmonary EmbolismDiagnosing pulmonary embolism (PE) involves clinical assessment and advanced imaging tests. The preferred diagnostic tool is the spiral (helical) CT scan or CT angiography (CTA), which uses intravenous contrast media to visualize the pulmonary vasculature and identify emboli.A ventilation-perfusion (V/Q) scan is an alternative for patients unable to receive contrast media. This scan includes both perfusion and ventilation scanning. Perfusion scanning involves...